Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Optimal Transport Guided Unsupervised Learning for Enhancing Low-Quality Retinal Images
Zhu, Wenhui , Qiu, Peijie , Farazi, Mohammad , Nandakumar, Keshav, Dumitrascu, Oana M. , Wang, Yalin

Mayo Clinic

2023 IEEE 20th International Symposium on Biomedical Imaging (ISBI) | September 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi53787.2023.10230719 | PMID 37736573 Get It

Three-level ACDF versus 3-level laminectomy and fusion: are there differences in outcomes? An analysis of the Quality Outcomes Database cervical spondylotic myelopathy cohort
Ambati, Vardhaan , Macki, Mohamed, Chan, Andrew K. , Michalopoulos, Giorgos D. , Le, Vivian , Jamieson, Alysha, Chou, Dean , Shaffrey, Christopher I. , Gottfried, Oren N., Bisson, Erica F. , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Park, Paul , Upadhyaya, Cheerag D., Shaffrey, Mark E., Buchholz, Avery L., Tumialán, Luis M. , Turner, Jay D. , Sherrod, Brandon A. , Haid, Regis W., Bydon, Mohamad , Mummaneni, Praveen V. , Michalopoulos, Giorgos , Ambati, Vardhaan

Mayo Clinic

Neurosurgical Focus | September 1, 2023 | Volume: 55 | Issue: 3 | Pages: E2

10.3171/2023.6.focus23295 | PMID 37657103 Get It

OBJECTIVE The authors sought to compare 3-level anterior with posterior fusion surgical procedures for the treatment of multilevel cervical spondylotic myelopathy (CSM). METHODS The authors analyzed prospective data from the 14 highest enrolling sites of the Quality Outcomes Database CSM module. They compared 3-level anterior cervical discectomy and fusion (ACDF) and posterior cervical laminectomy and fusion (PCF) surgical procedures, excluding surgical procedures crossing the cervicothoracic junction. Rates of reaching the minimal clinically important difference (MCID) in patient-reported outcomes (PROs) were compared at 24 months postoperatively. Multivariable analyses adjusted for potential confounders elucidated in univariable analysis. RESULTS Overall, 199 patients met the inclusion criteria: 123 ACDF (61.8%) and 76 PCF (38.2%) patients. The 24-month follow-up rates were similar (ACDF 90.2% vs PCF 92.1%, p = 0.67). Preoperatively, ACDF patients were younger (60.8 ± 10.2 vs 65.0 ± 10.3 years, p < 0.01), and greater proportions were privately insured (56.1% vs 36.8%, p = 0.02), actively employed (39.8% vs 22.8%, p = 0.04), and independently ambulatory (14.6% vs 31.6%, p < 0.01). Otherwise, the cohorts had equivalent baseline modified Japanese Orthopaedic Association (mJOA), Neck Disability Index (NDI), numeric rating scale (NRS)–arm pain, NRS–neck pain, and EQ-5D scores (p > 0.05). ACDF patients had reduced hospitalization length (1.6 vs 3.9 days, p < 0.01) and a greater proportion had nonroutine discharge (7.3% vs 22.8%, p < 0.01), but they had a higher rate of postoperative dysphagia (13.5% vs 3.5%, p = 0.049). Compared with baseline values, both groups demonstrated improvements in all outcomes at 24 months (p < 0.05). In multivariable analyses, after controlling for age, insurance payor, employment status, ambulation status, and other potential clinically relevant confounders, ACDF was associated with a greater proportion of patients with maximum satisfaction on the North American Spine Society Patient Satisfaction Index (NASS) (NASS score of 1) at 24 months (69.4% vs 53.7%, OR 2.44, 95% CI 1.17–5.09, adjusted p = 0.02). Otherwise, the cohorts shared similar 24-month outcomes in terms of reaching the MCID for mJOA, NDI, NRS–arm pain, NRS–neck pain, and EQ-5D score (adjusted p > 0.05). There were no differences in the 3-month readmission (ACDF 4.1% vs PCF 3.9%, p = 0.97) and 24-month reoperation (ACDF 13.5% vs PCF 18.6%, p = 0.36) rates. CONCLUSIONS In a cohort limited to 3-level fusion surgical procedures, ACDF was associated with reduced blood loss, shorter hospitalization length, and higher routine home discharge rates; however, PCF resulted in lower rates of postoperative dysphagia. The procedures yielded comparably significant improvements in functional status (mJOA score), neck and arm pain, neck pain–related disability, and quality of life at 3, 12, and 24 months. ACDF patients had significantly higher odds of maximum satisfaction (NASS score 1). Given comparable outcomes, patients should be counseled on each approach’s complication profile to aid in surgical decision-making.
Conditional, Tissue-Specific CRISPR/Cas9 Vector System in Zebrafish Reveals the Role of Nrp1b in Heart Regeneration
Angom, Ramcharan Singh , Wang, Ying , Wang, Enfeng , Dutta, Shamit K., Singh Angom, Ramcharan , Dutta, Shamit Kumar, Mukhopadhyay, Debabrata , Wang, Ying , Mukhopadhyay, Debabrata

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | August 31, 2023 | Volume: 43 | Issue: 10 | Pages: 1921-1934

10.1161/atvbaha.123.319189 | PMID 37650323 Get It

BACKGROUND: CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat-associated 9) technology-mediated genome editing has significantly improved the targeted inactivation of genes in vitro and in vivo in many organisms. Neuropilins play crucial roles in zebrafish heart regeneration, heart failure in mice, and electrical remodeling after myocardial infarction in rats. But the cell-specific functions of nrp1 have not been described before. In this study, we have investigated the role of nrp1 isoforms, including nrp1a and nrp1b , in cardiomyocytes during cardiac injury and regeneration in adult zebrafish hearts. METHODS: In this study, we have reported a novel CRISPR-based vector system for conditional tissue-specific gene ablation in zebrafish. Specifically, the cardiac-specific cmlc2 promoter drives Cas9 expression to silence the nrp1 gene in cardiomyocytes in a heat-shock inducible manner. This vector system establishes a unique tool to regulate the gene knockout in both the developmental and adult stages and hence widens the possibility of loss-of-function studies in zebrafish at different stages of development and adulthood. Using this approach, we investigated the role of neuropilin isoforms nrp1a and nrp1b in response to cardiac injury and regeneration in adult zebrafish hearts. RESULTS: We observed that both the isoforms ( nrp1a and nrp1b ) are upregulated after the cryoinjury. Interestingly, the nrp1b knockout significantly delayed heart regeneration and impaired cardiac function in the adult zebrafish after cryoinjury, demonstrated by reduced heart rate, ejection fractions, and fractional shortening. In addition, we show that the knockdown of nrp1b but not nrp1a induces activation of the cardiac remodeling genes in response to cryoinjury. CONCLUSIONS: To our knowledge, this study is novel where we have reported a heat-shock–mediated conditional knockdown of nrp1a and nrp1b isoforms using CRISPR/Cas9 technology in the cardiomyocyte in zebrafish and furthermore have identified a crucial role for the nrp1b isoform in zebrafish cardiac remodeling and eventually heart function in response to injury.
Predictive factors for decreased baseline quality of life in patients with sinonasal malignancies
Fleseriu, Cara M. , Beswick, Daniel M. , Maoz, Sabrina L. , Hwang, Peter H. , Chan, Erik, Adappa, Nithin D. , Getz, Anne E., Humphries, Ian M., Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Nabavizadeh, Seyed Ali , Adappa, Nithin D. , Patel, Zara M. , Smith, Timothy L. , Storm, Jay, Wang, Marilene B. , Choby, Garret , Kuan, Edward C , Humphreys, Ian M , Jafari, Aria , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Wang, Eric W , Beswick, Daniel , Hwang, Peter H , Maoz, Sabrina L , Choby, Garret , Adappa, Nithin D. , Geltzeiler, Mathew , Humphreys, Ian M. , Le, Christopher H. , Abuzeid, Waleed M. , Lee, Jivianne K., Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Resnick, Adam , John, Maie A. St. , Suh, Jeffrey D.

Mayo Clinic

International Forum of Allergy & Rhinology | August 30, 2023 | Volume: 14 | Issue: 4 | Pages: 775-785

10.1002/alr.23261 | PMID 37646428 Get It

AbstractBackgroundThe impact of sinonasal malignancies (SNMs) on quality of life (QOL) at presentation is poorly understood. The Sinonasal Outcome Test (SNOT‐22) and University of Washington Quality of Life (UWQOL) are validated QOL instruments with distinctive subdomains. This study aims to identify factors impacting pretreatment QOL in SNM patients to personalize multidisciplinary management and counseling.MethodsPatients with previously untreated SNMs were prospectively enrolled (2015–2022) in a multicenter observational study. Baseline pretreatment QOL instruments (SNOT‐22, UWQOL) were obtained along with demographics, comorbidities, histopathology/staging, tumor involvement, and symptoms. Multivariable regression models identified factors associated with reduced baseline QOL.ResultsAmong 204 patients, presenting baseline QOL was significantly reduced. Multivariable regression showed worse total SNOT‐22 QOL in patients with skull base erosion (p = 0.02). SNOT‐rhinologic QOL was worse in women (p = 0.009), patients with epistaxis (p = 0.036), and industrial exposure (p = 0.005). SNOT extranasal QOL was worse in patients with industrial exposure (p = 0.016); worse SNOT ear/facial QOL if perineural invasion (PNI) (p = 0.027). Squamous cell carcinoma pathology (p = 0.037), palate involvement (p = 0.012), and pain (p = 0.017) were associated with worse SNOT sleep QOL scores. SNOT psychological subdomain scores were significantly worse in patients with palate lesions (p = 0.022), skull base erosion (p = 0.025), and T1 staging (p = 0.023). Low QOL was more likely in the presence of PNI on UW health (p = 0.019) and orbital erosion on UW overall (p = 0.03). UW social QOL was worse if palatal involvement (p = 0.023) or PNI (p = 0.005).ConclusionsOur findings demonstrate a negative impact on baseline QOL in patients with SNMs and suggest sex‐specific and symptom‐related lower QOL scores, with minimal histopathology association. Anatomical tumor involvement may be more reflective of QOL than T‐staging, as orbital and skull base erosion, PNI, and palate lesions are significantly associated with reduced baseline QOL.
Prognostic and Diagnostic Utility of Serum Biomarkers in Pediatric Traumatic Brain Injury
Pareja, Jennifer C. Muñoz , Vaccari, Juan Pablo de Rivero , Chavez, Maria Mateo , Kerrigan, Maria, Pringle, Charlene , Guthrie, Kourtney, Swaby, Kathryn, Coto, Jennifer , Avery, K. Leslie , Ghosh, Suman , Dhanashree, Rajderkar, Shanmugham, Prashanth, Lautenslager, Lauren A. , Faulkenberry, Shannon, Zabala, María C. Pareja , Fakhri, Nora Al, Loor-Torres, Ricardo , Governale, Lance S., Blatt, Jason E. , Gober, Joslyn , Perez, Paula Karina, O’Phelan, Kristine , Dietrich, W. Dalton , Mateo Chavez, Maria B , Pringle, Charlene P , de Rivero Vaccari, Juan Pablo , Kobeissy, Firas , Solano, Juan, McCrea, Heather J. , Thorson, Chad M. , Keane, Robert W. , Wang, Kevin

Mayo Clinic

Journal of Neurotrauma | August 30, 2023 | Volume: 41 | Issue: 1-2 | Pages: 106-122

10.1089/neu.2023.0039 | PMID 37646421 Get It

Traumatic brain injury (TBI) remains a major cause of morbidity and death among the pediatric population. Timely diagnosis, however, remains a complex task because of the lack of standardized methods that permit its accurate identification. The aim of this study was to determine whether serum levels of brain injury biomarkers can be used as a diagnostic and prognostic tool in this pathology. This prospective, observational study collected and analyzed the serum concentration of neuronal injury biomarkers at enrollment, 24h and 48h post-injury, in 34 children ages 0–18 with pTBI and 19 healthy controls (HC). Biomarkers included glial fibrillary acidic protein (GFAP), neurofilament protein L (NfL), ubiquitin-C-terminal hydrolase (UCH-L1), S-100B, tau and tau phosphorylated at threonine 181 (p-tau181). Subjects were stratified by admission Glasgow Coma Scale score into two categories: a combined mild/moderate (GCS 9–15) and severe (GCS 3–8). Glasgow Outcome Scale-Extended (GOS-E) Peds was dichotomized into favorable (≤4) and unfavorable (≥5) and outcomes. Data were analyzed utilizing Prism 9 and R statistical software. The findings were as follows: 15 patients were stratified as severe TBI and 19 as mild/moderate per GCS. All biomarkers measured at enrollment were elevated compared with HC. Serum levels for all biomarkers were significantly higher in the severe TBI group compared with HC at 0, 24, and 48h. The GFAP, tau S100B, and p-tau181 had the ability to differentiate TBI severity in the mild/moderate group when measured at 0h post-injury. Tau serum levels were increased in the mild/moderate group at 24h. In addition, NfL and p-tau181 showed increased serum levels at 48h in the aforementioned GCS category. Individual biomarker performance on predicting unfavorable outcomes was measured at 0, 24, and 48h across different GOS-E Peds time points, which was significant for p-tau181 at 0h at all time points, UCH-L1 at 0h at 6–9 months and 12 months, GFAP at 48h at 12 months, NfL at 0h at 12 months, tau at 0h at 12 months and S100B at 0h at 12 months. We concluded that TBI leads to increased serum neuronal injury biomarkers during the first 0–48h post-injury. A biomarker panel measuring these proteins could aid in the early diagnosis of mild to moderate pTBI and may predict neurological outcomes across the injury spectrum.
Volumetric T 2 ‐weighted spin echo imaging with improved SNR using localized
Kim, Dahan , Wang, Dinghui , Chao, Tzu Cheng , Pipe, James G. , Campeau, Norbert, Pipe, James G , Campeau, Norbert G.

Mayo Clinic

Magnetic Resonance in Medicine | August 28, 2023 | Volume: 90 | Issue: 6 | Pages: 2261-2274

10.1002/mrm.29788 | PMID 37639386 Get It

Abstract Purpose To demonstrate T 2 ‐weighted (single‐echo) spin‐echo (SE) imaging with near‐optimal acquisition efficiency by applying SNR‐efficient RF slice encoding and spiral readout. Methods A quadratic‐phase (frequency swept) excitation RF pulse replaced the conventional excitation in T 2 ‐weighted SE sequence to excite a thick slab that is internally spatially encoded by a variable phase along the slice direction. Highly overlapping slabs centered at every desired slice location were acquired in multiple passes, such that the entire imaging volume was excited by contiguous slabs in any given pass. Following 90° excitation, each slab was refocused with a conventional 180° RF to produce a SE signal, followed by a spiral in‐out readout. A noise‐insensitive reconstruction removed the quadratic phase in the spatial frequency domain, yielding desired slice resolution and improved SNR. Results Increasing the RF frequency sweep (hence, excitation width) allowed more frequent encoding of each slice over the multiple passes, improving final image SNR, until crosstalk ensued at excessive slab widths compared to their center‐to‐center spacing. With an optimized slab width, the proposed technique used all passes to acquire every prescribed slice, with substantially improved SNR over conventional SE or 2D‐turbo‐spin‐echo (TSE) scans. Quantitative SNR measurements indicated similar SNR as 3D‐TSE, but radiologist scoring favored 3D‐TSE, mainly because of spiral‐related artifacts and possibly because of regularized reconstructions in 3D‐TSE. Conclusion Using SNR‐efficient slice excitation scheme and spiral readout helped eliminate SNR and temporal inefficiencies in conventional T 2 ‐weighted imaging, yielding SNR independent of TR or number of passes.
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction
Desai, Milind Y. , Owens, Anjali , Wolski, Kathy , Geske, Jeffrey B. , Wang, Andrew , Cremer, Paul , Lakdawala, Neal K. , Tower‐Rader, Albree, Naidu, Srihari S. , Smedira, Nicholas G. , McErlean, Ellen, Sewell, Christina , Mudarris, Lana, Gong, Zhiqun, Lampl, Kathy, Sehnert, Amy J. , Nissen, Steven E. , Geske, Jeffrey B , Cremer, Paul C , Wang, Andrew , Saberi, Sara , Sherrid, Mark V. , Fermin, David , Schaff, Hartzell V.

Mayo Clinic

JAMA Cardiology | August 28, 2023 | Volume: 8 | Issue: 10 | Pages: 968

10.1001/jamacardio.2023.3342 | PMID 37639243 Get It

Importance There is an unmet need for novel medical therapies before recommending invasive therapies for patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM). Mavacamten has been shown to improve left ventricular outflow tract (LVOT) gradient and symptoms and may thus reduce the short-term need for septal reduction therapy (SRT). Objective To examine the cumulative longer-term effect of mavacamten on the need for SRT through week 56. Design, Setting, and Participants This was a double-blind, placebo-controlled, multicenter, randomized clinical trial with placebo crossover at 16 weeks, conducted from July 2020 to November 2022. Participants were recruited from 19 US HCM centers. Included in the trial were patients with obstructive HCM (New York Heart Association class III/IV) referred for SRT. Study data were analyzed April to August 2023. Interventions Patients initially assigned to mavacamten at baseline continued the drug for 56 weeks, and patients taking placebo crossed over to mavacamten from week 16 to week 56 (40-week exposure). Dose titrations were performed using echocardiographic LVOT gradient and LV ejection fraction (LVEF) measurements. Main Outcome and Measure Proportion of patients undergoing SRT, remaining guideline eligible or unevaluable SRT status at week 56. Results Of 112 patients with highly symptomatic obstructive HCM, 108 (mean [SD] age, 60.3 [12.5] years; 54 male [50.0%]) qualified for the week 56 evaluation. At week 56, 5 of 56 patients (8.9%) in the original mavacamten group (3 underwent SRT, 1 was SRT eligible, and 1 was not SRT evaluable) and 10 of 52 patients (19.2%) in the placebo crossover group (3 underwent SRT, 4 were SRT eligible, and 3 were not SRT evaluable) met the composite end point. A total of 96 of 108 patients (89%) continued mavacamten long term. Between the mavacamten and placebo-to-mavacamten groups, respectively, after 56 weeks, there was a sustained reduction in resting (mean difference, −34.0 mm Hg; 95% CI, −43.5 to −24.5 mm Hg and −33.2 mm Hg; 95% CI, −41.9 to −24.5 mm Hg) and Valsalva (mean difference, −45.6 mm Hg; 95% CI, −56.5 to −34.6 mm Hg and −54.6 mm Hg; 95% CI, −66.0 to −43.3 mm Hg) LVOT gradients. Similarly, there was an improvement in NYHA class of 1 or higher in 51 of 55 patients (93%) in the original mavacamten group and in 37 of 51 patients (73%) in the placebo crossover group. Overall, 12 of 108 patients (11.1%; 95% CI, 5.87%-18.60%), which represents 7 of 56 patients (12.5%) in the original mavacamten group and 5 of 52 patients (9.6%) in the placebo crossover group, had an LVEF less than 50% (2 with LVEF ≤30%, one of whom died), and 9 of 12 patients (75%) continued treatment. Conclusions and Relevance Results of this randomized clinical trial showed that in patients with symptomatic obstructive HCM, mavacamten reduced the need for SRT at week 56, with sustained improvements in LVOT gradients and symptoms. Although this represents a useful therapeutic option, given the potential risk of LV systolic dysfunction, there is a continued need for close monitoring. Trial Registration ClinicalTrials.gov Identifier: NCT04349072
Evaluating Autoencoders for Dimensionality Reduction of MRI-derived Radiomics and Classification of Malignant Brain Tumors
Biggs, Mikayla , Wang, Yaohua , Soni, Neetu , Priya, Sarv , Bathla, Girish , Canahuate, Guadalupe , Priya, Sarv , Bathla, Girish , Wang, Yaohua

Mayo Clinic

35th International Conference on Scientific and Statistical Database Management | August 27, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.1145/3603719.3603737 | PMID 38344216 Get It

Terlipressin vs Midodrine Plus Octreotide for Hepatorenal Syndrome-Acute Kidney Injury: A Propensity Score–Matched Comparison
Chirikov, Viktor , Wang, Wei‐Jhih , Huang, Xingyue , Jamil, Khurram , Gonzalez, Stevan A , Simonetto, Douglas A.

Mayo Clinic

Clinical and Translational Gastroenterology | August 25, 2023 | Volume: 14 | Issue: 12 | Pages: e00627

10.14309/ctg.0000000000000627 | PMID 37622521 Get It

INTRODUCTION: Evidence on the comparison of treatments for hepatorenal syndrome-acute kidney injury (HRS-AKI) in a US population is limited. An indirect comparison of terlipressin plus albumin vs midodrine and octreotide plus albumin (MO) may provide further insight into treatment efficacy. METHODS: Cohorts of patients treated for HRS-AKI characterized by inclusion of patients with serum creatinine (SCr) <5 mg/dL and baseline acute-on-chronic liver failure grades 0–2 and exclusion of patients listed for transplant if model for end-stage liver disease scores ≥35 were pooled from (i) the CONFIRM and REVERSE randomized controlled trials (N = 159 meeting eligibility criteria from N = 216 overall, treated with terlipressin) and (ii) a retrospective review of medical records from 10 US tertiary hospitals (2016–2019; N = 55 treated with MO meeting eligibility criteria from N = 200 overall). The primary end point comparing the 2 cohorts was HRS reversal defined as achieving SCr ≤1.5 mg/dL at least once during the treatment. Covariate balancing propensity scoring was used to adjust for differences in baseline characteristics. RESULTS: HRS-AKI reversal was achieved in 52.35% of terlipressin-treated patients compared with 20% of MO-treated patients (adjusted mean difference 32.35%, 95% confidence interval [CI] 17.40–47.30, P < 0.0001). Terlipressin-treated patients had increased overall survival (adjusted hazard ratio 0.57, 95% CI 0.35–0.93, P = 0.02) but similar transplant-free survival (adjusted hazard ratio 0.79, 95% CI 0.53–1.17, P = 0.24). Achievement of HRS-AKI reversal was associated with increased OS and TFS regardless of treatment ( P < 0.001). DISCUSSION: Consistent with prior reports, terlipressin plus albumin is more effective in improving kidney function and achieving HRS-AKI reversal than MO plus albumin based on indirect comparison in a US population.
Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatment
Kosydar, Samuel , Parikh, Sameer A. , Rabe, Kari G. , Ding, Wei , Burlile, Jessica F. , Kenderian, Saad S. , Wang, Yucai , Muchtar, Eli , Koehler, Amber B. , Schwager, Susan M., Call, Timothy G. , Breen, William G. , Hampel, Paul J. , Kosydar, Samuel R , Lester, Scott C. , Chaffee, Kari G. , Ding, Wei , Burlile, Jessica , Kenderian, Saad Sirop , Wang, Yucai , Muchtar, E , Hampel, Paul J , Parikh, Sameer A , Slager, Susan L. , Kay, Neil E.

Mayo Clinic

American Journal of Hematology | August 24, 2023 | Volume: 98 | Issue: 11 | Pages: No page available

10.1002/ajh.27060 | PMID 37614209 Get It